Opinion|Videos|November 6, 2024

Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

Key Takeaways

  • Combination therapy in gMG is used for patients with severe symptoms or inadequate response to monotherapy, enhancing treatment efficacy.
  • Targeted treatments have revolutionized the management of newly diagnosed gMG patients, enabling more personalized therapeutic strategies.
SHOW MORE

Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.

Episodes in this series

Video content above is prompted by the following:

  • Phase 3 data of nipocalimab, an FcRn inhibitor, has recently been presented at the European Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine conferences in 2024. Please review the efficacy and safety data for nipocalimab in different patient populations.
  • What do phase 3 results add to phase 2 study findings with nipocalimab?
  • What are your thoughts about nipocalimab data for generalized myasthenia gravis (gMG)?
  • Please review the recently published data from the phase 3 trial of investigational FcRn inhibitor batoclimab for gMG.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Related Content